Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia

High-dose cytosine arabinoside therapy for refractory leukemia

1983 • 372 citations

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia

1989 • 294 citations

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

1991 • 255 citations

Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.

1988 • 222 citations

Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside

1965 • 206 citations

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1989 • 178 citations

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.

1986 • 168 citations

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

1987 • 163 citations

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.

1988 • 151 citations

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1986 • 139 citations

Central nervous system toxicity of fludarabine phosphate.

1986 • 122 citations

Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.

1990 • 114 citations

Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.

1986 • 105 citations

Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.

1987 • 98 citations

9-?-D-Arabinofuranosyl-2-fluoroadenine 5?-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

1986 • 91 citations

The use of intermediate dose cytosine arabinoside (ID Ara‐C) in the treatment of acute non‐lymphocytic leukaemia in relapse

1984 • 79 citations

Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo.

1988 • 71 citations

Biochemical Modulation of Arabinosylcytosine for Therapy of Leukemias

1993 • 60 citations

Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

1984 • 55 citations

OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside.

1991 • 33 citations

Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.

1983 • 29 citations

Experience with Intermediate and High Dose Cytosine Arabinoside in Refractory Acute Leukaemia

1983 • 18 citations

Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.

1986 • 18 citations